The U.S. Food and Drug Administration (FDA) approved the use of ivacaftor (Kalydeco®) today for people ages 2 and older with cystic fibrosis who have at least one of the following five splice mutations: 3849+10kbC->T, 2789+5G->A, 3272-26A->G, 711+3A->G, E831X.
Site Search
The U.S. Food and Drug Administration (FDA) today approved ivacaftor (Kalydeco®) for people ages 2 and older who have at least one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
This week, Congress approved a budget resolution that will allow lawmakers to make certain changes to the Affordable Care Act and Medicaid.
This week, Congress approved a budget resolution that will allow lawmakers to make certain changes to the Affordable Care Act and Medicaid.
On April 7, the Foundation presented the Alex, Jena, and Dream Big Awards to leaders in the cystic fibrosis community for their dedication to the Foundation's mission of finding a cure.
The Cystic Fibrosis Foundation today mourns the passing of legendary sports journalist Frank Deford, whose young daughter Alex lost her fight to CF in 1980, and who served as chair of the Cystic Fibrosis Foundation's Board of Trustees from 1982-1999.
As part of the Cystic Fibrosis Foundation's ninth annual Teen Advocacy Day, 162 advocates from 38 states met with elected officials in Washington, D.C., to tell their stories and make sure the cystic fibrosis community is heard in ongoing health care reform discussions.
Today, the Cystic Fibrosis Foundation announced that it will invest up to $8.4 million in SpliSense's Series B funding round to develop an antisense oligonucleotide therapy for people with cystic fibrosis who have splicing mutations and potentially other rare mutations.